secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001453687-24-000048
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.03, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian stockholders approve Series A conversion and 1-for-30 reverse split effective April 4
--------------------------------------------------------------------------------

- Stockholders approved issuance of common shares upon conversion of Series A Non-Voting Convertible Preferred Stock; automatic conversion set for April 8, 2024.
- Approved 1-for-30 reverse stock split effective after market close on April 4, 2024; trading on split-adjusted basis begins April 5 under RNAC.
- Post-split shares outstanding will drop from ~165.5M to ~5.5M (before conversion) or ~17.8M (after conversion of most preferred shares).
- No fractional shares; cash payment in lieu will be made; ~166.3K preferred shares remain subject to beneficial ownership limits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000048/0001453687-24-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000048/rnac-20240326.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer